STAT Breakthrough Summit East is only a few weeks away — register or apply now to join us in NYC or virtually for a day filled with thought-provoking programming.
As STAT Breakthrough Summit East approaches on March 21st, we're thrilled to unveil two sessions that bookend the hottest drug class in pharma — the GLP-1 inhibitors, which have become a social phenomenon and have driven the stocks of their makers to breathtaking highs.
We'll look at where these promising medicines could go — and what could slow their growth.
Can GLP-1s Help People with Addiction?
Nora Volkow, M.D., director, National Institute on Drug Abuse Elaine Chen, cardiovascular disease reporter, STAT (moderator)
We know them as treatments for diabetes and obesity, but lately, it seems like there is no limit to the potential uses of new medicines like Wegovy. Anecdotes say they reduce desires for alcohol and smoking. Could they help people with substance use problems?
GLP-1 Drugs: The Pushback Begins
Ross Hoffman, M.D., former chief medical officer, pharmacy/innovation, Centene Corporation; board member, advisor and investor Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
The new GLP-1 drugs for weight loss and diabetes have become, bar none, the hottest thing in medicine. Will insurers and governments find ways to contain their cost? A look at what tools are available and what can be done.
It is not too late to apply or register to attend. We hope to see you in NYC!
.gif?width=1200&upscale=true&name=STATSummitEast_Email_V2%20(1).gif)
.jpg?width=1120&upscale=true&name=2024%20BSE%20Sponsor%20Lock%20Up%20(1).jpg)
No comments